Kadmon Hlds

Kadmon Corporation, a biopharmaceutical company, offers products and services for the treatment and management of hepatitis C. Its products include Ribasphere RibaPak (ribavirin, USP) tablets, which help to reduce pill burden while providing patients with treatment that is biologically equivalent to other ribavirin medications; INFERGEN (interferon alfacon-1) to treat chronic hepatitis C in patients 18 years of age or older with compensated liver disease; Ribasphere (ribavirin, USP) tablets and capsules, which are antiviral medications for use in combination with other drugs for the treatment of chronic hepatitis C; and KD020, a reversible tyrosine kinase inhibitor that targets EGFR, HER2, VEGFR 2/3, and Src in autosomal dominant polycystic kidney disease (PKD). The company also provides various services and programs to support patients, prescribers, and pharmacies, including patient assistance programs to provide free medication to patients with limited or no insurance coverage; temporary shipments for patients on current or recent therapy; and nurse support services. In addition, it develops medicines in oncology, infectious diseases, immunology, and neurodegenerative diseases.  The company was formerly known as Kadmon Holdings. Kadmon Corporation was incorporated in 2009 and is based in New York, New York with operations in Warrendale, Pennsylvania; and Boston, Massachusetts.

Arcturus Therapeutics

Aurinia Pharmaceuticals

Chemocentryx

Novavax

Nevro

Thermo Fisher Scientific

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

7 “Perfect 10” Healthcare Stocks to Buy Now

There are high chances of KD025 securing FDA approval in cGVHD indication.

Kadmon Holdings: Pick Up This Late-Stage Biopharmaceutical Company In March 2020

Cidara Therapeutics

Callon Petroleum

NexTier Oilfield Solutions Inc

Ovid Therapeutics

QEP Resources

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

6 Cheap Stocks to Buy Under $7

Kadmon: Updates To Thesis, Pivotal cGVHD Data Impresses

Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.

Implied Volatility Surging for Kadmon (KDMN) Stock Options

Energy Transfer LP Unit

Replimune Group Inc

Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?

Largest Insider Trades of the Week (Nov 22)

Positive clinical trial results for the biopharmaceutical company's lead candidate, KD025, are driving investors' optimism.

Here's Why Kadmon Holdings Stock Jumped Today

Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant.

Kadmon biopharma shares rise on interim trial results

DURECT

Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.

3 Biotech Stocks That Could Double Your Money

Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).

Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD

Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know

Shares have lost a third of their value since my initial article.

Kadmon Holdings: Updates To Thesis, Systemic Sclerosis Study Gets Underway

Kadmon (KDMN) doses first patient in a phase II study of KD025 for the treatment of diffuse cutaneous systemic sclerosis (SSc).

News for Kadmon Hlds Stock (KDMN)